DWC202206 + DWC202207

**DWC202206 + DWC202207** is an investigational fixed-dose combination therapy under development for the treatment of patients with concomitant hypertension and hyperlipidemia. The combination is being studied in a randomized, double-blind, multicenter Phase III clinical trial to evaluate its efficacy and safety on two co-primary endpoints: the change in mean sitting systolic blood pressure (MSSBP) and the change in low-density lipoprotein cholesterol (LDL-C) from baseline. Both components (DWC202206 and DWC202207) are proprietary investigational agents developed by Daewoong Pharmaceutical; their individual mechanisms, components, and pharmacological classes remain undisclosed in public clinical trial summaries.